April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
What happens to visual acuity following removal of silicone oil?
Author Affiliations & Notes
  • Rachel Milne
    Ophthalmology, Ophthalmology Department, Gartnavel General Hospital, Glasgow, United Kingdom
  • David Miller
    Ophthalmology, Ophthalmology Department, Gartnavel General Hospital, Glasgow, United Kingdom
  • Kirstin Griffin
    Ophthalmology, Ophthalmology Department, Gartnavel General Hospital, Glasgow, United Kingdom
    Medical School, University of Glasgow, Glasgow, United Kingdom
  • David Yorston
    Ophthalmology, Ophthalmology Department, Gartnavel General Hospital, Glasgow, United Kingdom
  • Footnotes
    Commercial Relationships Rachel Milne, None; David Miller, None; Kirstin Griffin, None; David Yorston, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2341. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rachel Milne, David Miller, Kirstin Griffin, David Yorston; What happens to visual acuity following removal of silicone oil?. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2341.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Silicone oil is an effective tamponade in complex retinal detachment, including proliferative vitreoretinopathy (PVR), giant retinal tear (GRT) and proliferative diabetic retinopathy(PDR). However prolonged tamponade is associated with cataract, glaucoma, and reduced visual acuity. Whenever possible silicone oil is removed within a few months of its insertion. Although removal of silicone oil (ROSO) reduces the risk of complications, a few patients experience an unexplained drop in visual acuity, despite an apparently normal fundus. The purpose of this study was to estimate the incidence of this complication, and to identify any risk factors associated with it.

 
Methods
 

Retrospective case note review of 115 removal of silicone oil patients treated by 4 tertiary vitreoretinal consultants in the West of Scotland regional centre at Gartnavel General Hospital

 
Results
 

115 patients were included. Indications for silicone oil were PVR (68, 59%), PDR (14, 12%), Giant retinal tear (19, 17%). Following ROSO, 21 (18.3%) eyes redetached. Redetachment was not associated with the following risk factors: type of oil, duration of tamponade, 360 degree laser, retinectomy, PVR, PDR, GRT, or number of operations. The median LogMar (Fig.1) at presentation was 2.6, improving to 1.0 before ROSO (Mann-Whitney, p = 0.0005), and 0.78 after ROSO (Mann-Whitney, p = 0.0084). In the 94 eyes that remained attached, corrected vision improved by ≥0.3 LogMar units in 39 (41.1%, 95% ci 31.2-51.6%), and worsened by ≥0.3 LogMAR in 5 (5.3%, 95% ci 2.0 - 12.6%). 50 patients (52.6%, 95% ci 42.2 - 62.9%)had little change in VA. In four eyes (4.3%, 95%ci 1.4-11.2%) there was no apparent cause for the loss of vision. Vision deterioration or improvement following ROSO was not associated with presenting visual acuity, indication for silicone oil, type of oil, duration of tamponade, 360 degree laser, retinectomy, or number of operations.

 
Conclusions
 

VA is improved or stabilized in most patients having ROSO. Although unexplained reduction in vision is a well-known complication, this is the first report that attempts to estimate the incidence. Our data suggests that the complication may be more common than originally thought. All patients undergoing ROSO should be informed of the risk of unexplained visual loss as well as the risk of redetachment.

 
 
Fig.1 Box plot of LogMAR visual acuities at presentation, prior to ROSO, and after ROSO.
 
Fig.1 Box plot of LogMAR visual acuities at presentation, prior to ROSO, and after ROSO.
 
Keywords: 754 visual acuity • 762 vitreoretinal surgery • 697 retinal detachment  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×